Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
featured
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCl in Postmenopausal Women with Metastatic, Estrogen Receptor Positive, HER2 Negative Breast Cancer

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCl in Postmenopausal Women with Metastatic, Estrogen Receptor Positive, HER2 Negative Breast Cancer

tamoxifen
estrogen receptor
estrogen
HER2
breast cancer
  • 378 views
  • 23 Nov, 2020
  • 1 location
featured
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study

ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study

breast cancer
estrogen receptor
estrogen
  • 150 views
  • 23 Nov, 2020
  • 1 location
featured
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

  • 332 views
  • 08 Nov, 2020
  • 1 location
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

CYP2D6 intermediate/poor metabolizers of premenopausal patients with estrogen receptor-positive early breast cancer.

neutrophil count
tamoxifen
mastectomy
cancer
estrogen receptor
  • 28 views
  • 21 Jan, 2021
  • 18 locations
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low Hormone Receptor Positive Metastatic Breast Cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

  • 35 views
  • 17 Jan, 2021
  • 183 locations
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. …

doxorubicin
tamoxifen
adjuvant therapy
immunostimulant
epirubicin
  • 33 views
  • 07 Nov, 2020
  • 1 location
Exemestane Letrozole or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

Researchers have been studying breast cancer to learn the best way to treat the disease. Chemotherapy (treatment with anti-cancer drugs) is commonly given before surgery to shrink breast tumors. Research has shown that reducing the amount of the hormone estrogen that gets to the cancer in postmenopausal women with hormone-dependent …

estrogen
anastrozole
exemestane
letrozole
hormone therapy
  • 6 views
  • 07 Nov, 2020
  • 1 location
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal growth factor receptor 2 (HER2) negative or

neutrophil count
doxorubicin
carcinoma
bilateral breast cancer
epidermal growth factor receptor
  • 0 views
  • 24 Jan, 2021
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer

This is a phase I study looking at the safety of cancer peptides combined with adjuvant and GM-CSF in subjects with estrogen receptor (ESR) positive breast cancer. The primary objective of the

estrogen
immunostimulant
ESR1
estrogen receptor
  • 0 views
  • 25 Jan, 2021
  • 1 location
FES (16 -[18F]-Fluoro-17 -estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET

computed tomography (CT). However, previous studies have shown that this technique (with the current PET tracer) might not be sufficient for accurate staging. Specifically in low grade, estrogen receptor

estradiol
estrogen
her2/neu-negative breast cancer
metastasis
HER2
  • 1 views
  • 14 Oct, 2020
  • 1 location